The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Traws Pharma Positions Long-Acting Antivirals for Influenza and Outbreak Threats as Sector Opportunities Expand
Source: Streetwise Reports (06/20/2026)

Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors.

Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth
Source: Streetwise Reports (06/20/2026)

Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities.

Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors.

Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors.

Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors.